-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Biogen, Raises Price Target to $290

Benzinga·10/29/2026 11:11:37
Listen to the news
Baird analyst Brian Skorney maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $250 to $290.